Literature DB >> 20550561

Sleep disorders in Wilson's disease.

S Nevsimalova1, J Buskova, R Bruha, D Kemlink, K Sonka, L Vitek, Z Marecek.   

Abstract

BACKGROUND: Wilson's disease (WD) is an autosomal recessive inherited disease with copper accumulation; neurodegeneration is associated with dopaminergic deficit. The aim of the study is to verify sleep co-morbidity by questionnaire and objective sleep examinations (polysomnography, multiple sleep latency test).
METHODS: fifty-five patients with WD (22 hepatic, 28 neurological, five asymptomatic form) and 55 age- and sex-matched control subjects completed a questionnaire concerning their sleep habits, sleep co-morbidity, Epworth sleepiness scale (ESS), and answered screening questions for rapid eye movement (REM) behaviour disorder (RBD-SQ). Twenty-four patients with WD and control subjects underwent polysomnographic examination.
RESULTS: unlike the controls, patients with WD were more prone to daytime napping accompanied by tiredness and excessive daytime sleepiness, cataplexy-like episodes and poor nocturnal sleep. Their mean ESS as well as RBD-SQ was higher than that of the controls. Total sleep time was lower, accompanied by decreased sleep efficiency and increased wakefulness. Patients with WD had lower latency of stage 1 and stage 2 of non-rapid eye movement (NREM) sleep and less amount of NREM sleep stage 2. One-third of the patients with WD were found to have short or borderline multiple sleep latency test (MSLT) values independent of nocturnal pathology (sleep apnoea, periodic leg movements and/or restless leg syndrome).
CONCLUSIONS: patients with WD often suffer from sleep disturbances (regardless of the clinical form). The spectrum of sleep/wake symptoms raises the suspicion that altered REM sleep function may also be involved.

Entities:  

Mesh:

Year:  2011        PMID: 20550561     DOI: 10.1111/j.1468-1331.2010.03106.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  18 in total

Review 1.  Update on the Diagnosis and Management of Wilson Disease.

Authors:  Eve A Roberts
Journal:  Curr Gastroenterol Rep       Date:  2018-11-05

2.  Hypersomnolence in Wilson Disease.

Authors:  Valerie C Amann; Neal K Maru; Vivek Jain
Journal:  J Clin Sleep Med       Date:  2015-11-15       Impact factor: 4.062

Review 3.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 4.  Copper and the brain noradrenergic system.

Authors:  Svetlana Lutsenko; Clorissa Washington-Hughes; Martina Ralle; Katharina Schmidt
Journal:  J Biol Inorg Chem       Date:  2019-11-05       Impact factor: 3.358

5.  Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.

Authors:  Radan Bruha; Libor Vitek; Zdenek Marecek; Lenka Pospisilova; Sona Nevsimalova; Pavel Martasek; Jaromir Petrtyl; Petr Urbanek; Alena Jiraskova; Ivana Malikova; Martin Haluzik; Peter Ferenci
Journal:  J Inherit Metab Dis       Date:  2011-12-03       Impact factor: 4.982

6.  Sleep disorders in Wilson disease: a systematic review and meta-analysis.

Authors:  Jinyang Xu; Qingqing Deng; Qingsong Qin; Alexandros N Vgontzas; Maria Basta; Chanyan Xie; Yun Li
Journal:  J Clin Sleep Med       Date:  2020-01-13       Impact factor: 4.062

Review 7.  Sleep Disorders in Wilson's Disease.

Authors:  Valérie Cochen De Cock; France Woimant; Aurélia Poujois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

8.  Metals and Circadian Rhythms.

Authors:  Nancy L Parmalee; Michael Aschner
Journal:  Adv Neurotoxicol       Date:  2017-09-01

9.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

Review 10.  Sleep Abnormalities in Wilson's Disease.

Authors:  Valérie Cochen De Cock; Nadège Girardot-Tinant; France Woimant; Aurélia Poujois
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.